Otsuka Holdings Co., Ltd.

¥11,585As of Sun 8 Nov 2026, 12:00 UTC

TSE:4578Healthcare

Country Japan

PE (Fwd) •••

TSR 10Y CAGR 11.91%

Div yield 1.73%

ROE 12.60%

Drug Manufacturers (General)

Beta (5Y) (0.06)

PE TTM 15.74

TSR TTM 40.70%

Mkt cap ¥6.069T

ROIC 12.65%

SE Grade™

Value

Quality

Moat

Consensus

Reference

¥12,429

7.29%

(77.12%)

Hold 5|9|1|12|1

TTM

FYE 31 Dec JPY

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

697.2

Revenue¥B

1,173

1,244

1,323

1,434

1,524

1,625

1,726

1,845

1,941

2,074

777.5

6.36%

6.57%

10.48

Revenue growth%

16.44

15.81

16.95

14.04

16.96

17.66

19.14

18.05

20.97

20.60

22.22

19.14

17.31

7.13

Gross margin%

14.38

12.75

13.41

13.87

15.05

14.82

14.41

16.48

14.20

2.27

14.41

14.39

16.64

Operating margin%

9.70

9.50

11.02

11.40

10.45

9.47

9.65

12.32

13.56

15.54

15.79

12.32

10.74

23.37

Net margin%

1.37

0.40

1.06

0.40

2.35

0.90

2.19

7.02

0.90

0.65

19.00

P/E ratio (avg)x

54.28

65.21

69.04

81.86

80.19

85.88

87.38

99.12

102.2

112.3

37.53

99.12

83.87

21.23

EV/EBITx

8.374

8.992

8.158

8.649

8.181

8.955

9.325

8.952

9.871

9.546

34.77

9.325

8.953

12.19

FCF yield (avg)%

18.71

17.05

17.60

18.34

19.90

21.85

23.10

21.64

22.09

20.49

22.84

21.85

20.19

2.37

FCF margin%

4.08

1.56

0.40

2.02

0.74

0.47

0.40

2.06

0.40

0.55

17.59

0.47

0.65

1.014

FCF / Net incomex

2.045

2.449

2.658

3.158

3.225

3.444

3.387

3.608

4.139

4.244

0.774

3.608

3.306

26.86

ROIC%

19.09

18.04

16.67

18.99

19.48

18.09

20.20

22.49

20.56

19.27

2.62

20.20

19.18

22.59

Return on equity%

12.65

9.97

7.58

9.90

11.02

11.88

14.63

15.04

16.35

13.36

10.44

14.63

12.26

29.80

Return on assets%

12.18

10.17

8.26

10.78

8.34

7.37

6.45

5.72

4.80

15.28

6.45

8.30

1,073

EPS¥

293.22

307.27

368.88

400.30

408.96

484.67

472.24

476.77

501.19

534.07

1,125

5.48%

6.59%

—

14.05

EPS growth%

7.95

6.75

3.90

1.60

3.43

3.12

0.90

0.40

2.05

4.23

8.60

2.05

3.28

394.95

Bookvalue per sh¥

662.34

631.23

662.39

740.27

771.73

888.61

843.95

878.18

924.06

1,091

466.82

7.17%

6.38%

—

515.70

FCF per share¥

695.16

636.59

673.70

599.79

571.36

501.49

457.04

477.14

449.35

490.69

610.75

(3.00%)

(2.63%)

—

943.22

Dividend per sh¥

551.10

622.12

660.86

778.97

882.59

996.21

945.54

964.27

970.41

1,107

529.42

4.64%

6.99%

—

18.40

Div yield (avg)%

27.76

30.48

28.10

25.25

27.70

30.39

29.14

27.21

25.70

28.23

9.15

28.23

27.93

13.75

Payout ratio%

29.95

28.44

27.13

30.11

31.95

31.66

34.42

31.46

31.60

31.34

17.80

31.60

31.40

0.516

Shares (diluted)B

0.695

0.772

0.859

0.844

0.865

1.015

1.008

1.035

0.992

1.094

0.523

4.80%

5.20%

2.85

Buyback yield%

8.03

7.38

6.33

7.87

5.12

7.50

5.18

7.04

8.99

7.26

25.07

7.26

7.32

0.389

D/E ratiox

1.086

0.977

0.978

0.907

0.964

0.985

1.052

0.969

0.957

0.955

0.829

0.969

0.973

1,879

Enterprise value¥B

1,354

1,372

1,415

1,341

1,142

1,199

1,258

1,187

1,044

965.5

1,259

(3.30%)

(2.54%)

1,150

LT debt¥B

2,422

2,363

2,676

2,903

2,998

3,023

3,476

3,924

4,025

4,711

183.6

9.46%

7.28%

Peers (US$38.54B)

Cap (US$)

Chugai Pharmaceutical…

71.10B

22.24x

Daiichi Sankyo Company…

32.01B

18.09x

Astellas Pharma Inc.

28.14B

11.52x

Biogen Inc.

36.71B

106.3x

Capital

TTM

10Y

Leveragex

3.987

(0.601)

(0.466)

EBIT/Intx

0.967

0.686

0.641

Own earn%

(36.99)

65.20

65.11

Sh yield%

21.25

34.69

34.56

Owners

Insiders/Inst%

5.18

83.28

Short interest%

1.96

SBC / revenue%

2.75

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

9–16

$1 testx

—

Incr. ROIC%

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

¥2.074T

6.57%

1.00×

Cost of revenue

¥1.452T

6.57%

1.00×

Operating expenses

¥322.0B

7.29%

1.07×